id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-P-0888-0004,FDA,FDA-2011-P-0888,FDA/CDER to Foley & Lardner LLP - Letter,Other,Letter(s),2012-04-18T04:00:00Z,2012,4,2012-04-18T04:00:00Z,,2012-04-18T16:30:17Z,,0,0,0900006480ff35ea
FDA-2011-P-0888-0003,FDA,FDA-2011-P-0888,"Determinations that  FUNDUSCEIN-25 (fluorescein sodium injection), 25 Percent, and AK-FLUOR (fluorescein sodium injection), 25 Percent, were Not Withdrawn from Sale for Reasons of Safety or Effectiveness",Notice,General Notice,2012-04-18T04:00:00Z,2012,4,2012-04-18T04:00:00Z,,2012-04-18T14:34:46Z,2012-09292,0,0,0900006480ff342f
FDA-2011-P-0888-0001,FDA,FDA-2011-P-0888,Foley & Lardner LLP - Citizen Petition,Other,Citizen Petition,2011-12-09T05:00:00Z,2011,12,2011-12-09T05:00:00Z,,2012-04-18T14:26:28Z,,0,0,0900006480f7e4a1
FDA-2011-P-0888-0002,FDA,FDA-2011-P-0888,Acknowledgement Letter to Foley & Lardner LLP,Other,Acknowledgement Letter/Receipt,2011-12-09T05:00:00Z,2011,12,2011-12-09T05:00:00Z,,2011-12-10T00:28:51Z,,0,0,0900006480f7e4b9